Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.375 11.54% 3.625 615,418 11:14:02
Bid Price Offer Price High Price Low Price Open Price
3.50 3.75 3.625 3.25 3.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.12 -2.74 5
Last Trade Time Trade Type Trade Size Trade Price Currency
16:00:47 O 30,000 3.525 GBX

Evgen Pharma (EVG) Latest News

More Evgen Pharma News
Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma (EVG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:00:483.5330,0001,057.50O
12:05:333.5340,0001,410.00O
11:11:563.68108,6953,999.98O
10:29:303.53100,0003,525.00O
10:21:433.7026,902995.05O
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

DateSubject
31/3/2020
09:20
Evgen Pharma Daily Update: Evgen Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 3.25p.
Evgen Pharma Plc has a 4 week average price of 2.75p and a 12 week average price of 2.75p.
The 1 year high share price is 24.50p while the 1 year low share price is currently 2.75p.
There are currently 132,646,263 shares in issue and the average daily traded volume is 69,474 shares. The market capitalisation of Evgen Pharma Plc is £4,808,427.03.
17/1/2020
08:54
dave444: Well it has sparked EVG share trading into life
15/1/2020
15:09
timbo003: There were four Evgen attendees at the meeting: Steve Franklin (CEO), Richard Moulson (CFO), Barry Clare (Chairman) and Sally Ross (Clinical Dev Officer) Steve went over most of the slides, with Sally covering those which were clinically related. The link to the slide set is here: https://walbrookpr.com/investors/pdf/Evgen-Pharma-plc-company-presentation.pdf The points that struck me as most interesting were as follows: Sulforaphane is believed to act via two different mechanisms * Nrf2 activation (possible treatment of multiple indications including, Autism and NASH, see slide 20) * SAT3 inhibition (prevention of metastases in cancers) The only other quoted pharma specialising in Nrf2 activators is Reata Pharmaceuticala, who have two Nrf2 activator compounds in Phase III clinical development targeting 4 different indications (plus ample cash to complete the programs). Reata are quoted on Nasdaq and have a market cap of $7Bn https://uk.finance.yahoo.com/quote/RETA?p=RETA&.tsrc=fin-srch-v1 https://www.reatapharma.com/ https://www.fiercebiotech.com/keyword/reata-pharmaceuticals (for reference: Market cap for Evgen is currently £7.5m and they had around £5m cash at the end of Sept) The role of SAT3 in metastases is a rapidly developing field and is not yet fully understood, but Evgen’s collaborators are in the process of publishing a review paper on the subject in a high impact journal (available within a month or so) which will include much of their own work and reference the recent STEM study. This should increase general awareness of SAT3 and the potential of inhibitors of SAT3 (such as sulforaphane) to prevent metastases. Evgen are currently well funded (£5m at end of Sept), the cash will mainly be spent on: * Additional tox studies, allowing them to dose beyond 28 days for other indications (i.e. autism and Nash) not just late stage cancer. * Development of a tablet formulation for use in proposed studies in Autism, Nash and Breast cancer (Formulation used in first two studies was a giant hand filled capsule) * Preparing for a second (controlled) study in breast cancer Evgen have no intention to raise funds at around the current share price. The proposed studies on Autism (Guys, London) and NASH (Dundee) will be via non- dilutive funding, these agreements are yet to be finalised, as the institutions are in the process of obtaining grant approval, but it is anticipated that the “normal commercial terms” refered to in the RNS announcements will only concern a few milestone payments, there will probably be no royalties and if there were any, they would be reassuringly small. For the work on Sulforaphane analogues at Saville, Evgen conducted two separate tests (Nrf2 activation and anti-metastases assay). They got some hits for both assays, although none of the 40 – 50 compounds were as potent as sulforaphane for Nrf2 activation. This work is complete and there are no further obligations for further work (or payments) they could (if they wish) now sit on this and maintain the patents (until expiry) to reinforce the IP around sulforaphane (note: from what I can gather it was the Chairman, Barry Clare who championed this work). There is currently some work ongoing regarding the crystal structure of SFX-01 which suggests there are more than one polymorph and different polymorphs may have different stability characteristics, this could help extend the IP out to 2040. The results for the SAH study were obviously disappointing. It is possible that they may have been better, if dosing could have been continued beyond 28 days. The results were analysed in every way possible to look for trends, there was a trend observed in favour of the active in one of the variables measured, but this could be accounted for by the number of multiple comparisons conducted (i.e. it was through chance). The patients from the placebo group responded better than expected and the (low) mortality rate was the same for both the active and placebo groups. Furthermore the blood flow measurements (primary variable) for many of the patients showed more variability than normally observed for SAH patients. The three major pharmas who are likely to be the most interested in partnering Sulforaphane for breast cancer are Novartis, Lilly and Pfizer (these are the three pharmas which market the CDK4/6 inhibitors which are used to treat metastatic breast cancer), see slide 27 of slide deck. Breast cancer cells eventually develop resistance to CDK4/6 inhibitors (and Aromatase inhibitors/ER modulators) and it is believed that sulforaphane acts by preventing resistance developing. Evgen have discussed the STEM data with big pharmas and they have expressed interest, but the general comment is that they would like to see more data (from a larger controlled study).
12/11/2019
15:06
asat91: It is an interesting opportunity this because it's a pharma with an asset that has positive data in one indication at phase II, and non-significant (negative data) in another indication at phase II. Does the negative data for SAS indication warrant a share price drop of 60%, and a market cap of 10 million? Is 10 million fair value for what the company has at the moment? That's the golden question. Maybe the answer is yes, maybe it is no. What do you think?
13/10/2019
13:18
pennyfalls: Problem is, the trading cycle becomes a self-fulfilling prophecy. Each item of good news (and there’s been many) brings an attendant spike, then slowly but surely back to the support levels circa 13.5p-15p (and maybe even testing an all-time low one this time), plus fundraiser. So investors see the well-defined pattern and act accordingly. However at some point there will be (should be) an inflection point where traction holds with the share price. This could be positive SAH + forward funding/licensing then Autism trials etc (coming in quick succession), or it could be further down the line at SAH phaseIII or next STEM trials. But all depends on the next RNS being a good one, so I’ll take it from there and see what comes
11/10/2019
20:05
90005nelson: The Directors have good skin in the game here. There's also two chances of success with SFX-01 from STEM & SAH. EVG has stated that potential partners need to pay an upfront payment of $50M & &70M. Companies house has been fully updated. The removal of pre-emption rights. There's movement behind the scenes as we wait for the SAH results. Orphan drug status is obtained as with virtually all the worldwide patents. I don't expect the share price to be at this level within next few months.
11/10/2019
19:40
pennyfalls: All posts look quite positive to me Dave, with some good knowledge. Outcome wont be linked to ADVFN posts, and neither will Share price.
10/10/2019
15:05
90005nelson: I agree with your timeline for the news. LTH are also derisking as they watch previous profits evaporate.The share price is now below my average and represents 13.3% of my portfolio. I'm happy to divert other profits, as & when, into the lower price.
26/9/2019
12:29
timbo003: A few thoughts following some of the recent comments on the SAH study First of all, it is worth bearing in mind the market’s perceived potential value (and risk adjusted value) of the company’s clinical assets: Finncap Initiation note (April 2019) Metastatic breast cancer value of (£30m) 30p per share that would rise to c.£60m (60p) on a successful Phase IIb study. This excludes any upfront licensing payment that would be expected on successful completion of the proposed Phase IIb study. This could be of the order of order of $50m or c.35-40p per share. The de-risked NPV is c.£300m (excluding upfronts and/or milestones). Subarachnoid haemorrhage value of £14m (15p per share). A positive readout of its Phase IIb study in Q3 2019 would value the potential royalty stream at c.£50m, which together with the value of a potential upfront payment (c.£30m), should the company license the asset, implies an asset value of c.£80m. Our target price attributes no value to any investigator-initiated studies in which Evgen would supply SFX-01 for Phase II trials in fatty liver disease (NASH), autism spectrum disorder and intra-cerebral haemorrhage (ICH) whilst retaining all commercial rights. Our target price valuation would rise to at least c.£80m (80p) on a successful Phase IIb trial result in SAH. The downside risk, should the trial fail, is around 7p in our opinion. The current share price is more than supported by the breast cancer indication alone (c.30p). Finncap update (May 2019) The Phase IIb trial of SFX-01 in subarachnoid haemorrhage (SAH) is expected to readout in Q3 2019, following advice from clinicians and statisticians to leave the study blinded until completion of both primary and secondary cognitive endpoints at six months post treatment. A successful outcome would see our risk-adjusted value for this indication rise from c.£15m to c.£80m. Our forecasts are unchanged apart from cash and LPS, which is reduced to take account of the 25% enlargement of share capital. Our target price is reduced to 35p to reflect this dilution. Our risk-adjusted target valuation of c.£45m would rise to c.£110m upon a successful Phase IIb readout for SAH, implying an increase in the target price to c.85p. On March 18th the company stated: Following advice from clinicians and statisticians, and in the light of commercial considerations, the Company has decided to announce the primary endpoints (safety, tolerability and measures of blood flow in the brain) and secondary endpoints (relating to cognitive function) at the same time, rather than announcing them separately as previously indicated. I would have been very surprised if they hadn’t taken that decision given the study design. The primary outcome is cerebral blood flow and one of the the secondary outcomes is cognitive function ( 7 , 28, 90 and 180 days post stroke). In reality, everyone (i.e. Clinicians, Investors and potential partners) will be far more focused on the secondary than the primary, so why compromise the blinding (and the statistical significance) for the outcome which is of most interest by prematurely analysing and reporting result from the primary measure (which will be of much less interest)? This is particularly relevant in the SAH study as the cognitive function will be assessed using the modified Rankin scale (0-6 ordinal scale) https://clinicaltrials.gov/ct2/show/NCT02614742?term=evgen&rank=2 This will inevitably involve some subjectivity when assigning a score (with the obvious exception of scoring a maximum 6), therefore it extremely important to maintain the integrity of the blinding https://en.wikipedia.org/wiki/Modified_Rankin_Scale http://www.modifiedrankin.com/input? Given the lack lustre share price action in the last few weeks, investors are bound to ask themselves, does someone already know the outcome of the study? I think the answer to that is almost certainly no, with the small caveat that in some blinded studies where the design is control vs active, it is sometimes possible for the investigator to make an educated guess as to whether the active is having any effect, for example when one of the outcomes is unavoidably obvious (for example mortality rate). For SAH on average around 40% of patients on standard of care die within 30 days and for the survivors c.50% will have long-term cognitive impairment, so if the investigator sees no perceptible improvement for these measures when looking at the combined blinded placebo and active treatments, they may come to the conclusion that the active treatment is probably ineffective, on the other hand if they see the mortality rate at 30% or lower and improved (lower) Rankin scores, they may conclude that the active is probably having an effect.
24/9/2019
10:09
asat91: Well I was about to share similar concerns so don't regret sharing too much. The overly positive tone of the most recent RNS releases about breast cancer results are what indicate to me that they are worried about the SAH results and trying to avoid a significant share price drop. I mean why are they even releasing an RNS on the breast cancer results! The results came out a while back, and there's nothing new in these releases that requires sharing with shareholders. So why upload it at all? The timing seems very coincidental 1/2 months before SAH results.
13/6/2018
12:14
teddy boy1: There should be a law against what has happened this morning ;the way the share price was systematically taken down to encourage more sales.This share is definitely being "worked " and the bottom line is that all the shorters and the market makers have made themselves a shed load of money over the past 3 days- and this is on a GOOD trial update ! Think of what would have happened if the news had been bad! On second thoughts the share price would not have been too much different ,left to its own devices. Anyhow this is AIM , and this is how things are ! Perhaps companys such as EVGEN and IDP with very tightly held shares should be avoided like the plague as they are prime candidates for manipulation . With such companys;until they have proved themselves 100 per cent, the seeds of doubt will be sown and before we know where we are the share price has been worked down until the share price bears no resemblance to its true value. This is a real pity as I have not read anything myself which would encourage me to dispose of my shares as, as far as I am concerned ,Evgen Pharma has a very bright future .However ,it could still be many months/years before we are allowed a TRUE share price which values the company for what it is worth and not what some individuals CAUSE it to be, in the quest to make some easy money for themselves, over and over again! Anyone else agree with my sentiments?
Evgen Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200331 17:49:00